|
1
|
Kitahara CM and Sosa JA: The changing
incidence of thyroid cancer. Nat Rev Endocrinol. 12:646–653. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schneider DF, Chen H and Sippel RS: Impact
of lymph node ratio on survival in papillary thyroid cancer. Ann
Surg Oncol. 20:1906–1911. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee YM, Lo CY, Lam KY, Wan KY and Tam PK:
Well-differentiated thyroid carcinoma in Hong Kong Chinese patients
under 21 years of age: A 35-year experience. J Am Coll Surg.
194:711–716. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mazzaferri EL and Massoll N: Management of
papillary and follicular (differentiated) thyroid cancer: New
paradigms using recombinant human thyrotropin. Endocr Relat Cancer.
9:227–247. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Giannoula E, Iakovou I and Verburg FA:
Long term quality of life in differentiated thyroid cancer patients
after thyroidectomy and high doses of 131I with or
without suppressive treatment. Hell J Nucl Med. 21:69–73.
2018.PubMed/NCBI
|
|
6
|
Ronga G, Toteda M, D'Apollo R, De
Cristofaro F, Filesi M, Acqualagna G, Argirò R, Ciancamerla M,
Ugolini F and Montesano T: Lymph node metastases from
differentiated thyroid carcinoma: Does radioiodine still play a
role? Clin Ter. 163:377–381. 2012.PubMed/NCBI
|
|
7
|
Kim WG, Ryu JS, Kim EY, Lee JH, Baek JH,
Yoon JH, Hong SJ, Kim ES, Kim TY, Kim WB and Shong YK: Empiric
high-dose 131-iodine therapy lacks efficacy for treated papillary
thyroid cancer patients with detectable serum thyroglobulin, but
negative cervical sonography and 18F-fluorodeoxyglucose positron
emission tomography scan. J Clin Endocrinol Metab. 95:1169–1173.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bertagna F, Albano D, Bosio G, Piccardo A,
Dib B and Giubbini R: 18F-FDG-PET/CT in patients affected by
differentiated thyroid carcinoma with positive thyroglobulin level
and negative 131I whole body scan. It's value confirmed by a
bicentric experience. Curr Radiopharm. 9:228–234. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu YH, Shen CT, Xue YL, Qiu ZL and Luo QY:
Iodine-131 SPET/CT and 18F-FDG PET/CT for the identification and
localization of mediastinal lymph node metastases from
differentiated thyroid carcinoma. Hell J Nucl Med. 16:199–203.
2013.PubMed/NCBI
|
|
10
|
Wang QC, Cheng W, Wen X, Li JB, Jing H and
Nie CL: Shorter distance between the nodule and capsule has greater
risk of cervical lymph node metastasis in papillary thyroid
carcinoma. Asian Pac J Cancer Prev. 15:855–860. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van den Brekel MW, Stel HV, Castelijns JA,
Nauta JJ, van der Waal I, Valk J, Meyer CJ and Snow GB: Cervical
lymph node metastasis: Assessment of radiologic criteria.
Radiology. 177:379–384. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lodge MA, Chaudhry MA and Wahl RL: Noise
considerations for PET quantification using maximum and peak
standardized uptake value. J Nucl Med. 53:1041–1047. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Turk A, Asa SL, Baloch ZW, Faquin WC,
Fellegara G, Ghossein RA, Giordano TJ, LiVolsi VA, Lloyd R, Mete O,
et al: Interobserver variability in the histopathologic assessment
of extrathyroidal extension of well differentiated thyroid
carcinoma supports the new american joint committee on cancer
eighth edition criteria for tumor staging. Thyroid. Apr
27–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wahl RL, Jacene H, Kasamon Y and Lodge MA:
From RECIST to PERCIST: Evolving considerations for PET response
criteria in solid tumors. J Nucl Med. 50 (Suppl 1):122S–150S. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shaha AR: Prognostic factors in papillary
thyroid carcinoma and implications of large nodal metastasis.
Surgery. 135:237–239. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Podnos YD, Smith D, Wagman LD and
Ellenhorn JD: The implication of lymph node metastasis on survival
in patients with well-differentiated thyroid cancer. Am Surg.
71:731–734. 2005.PubMed/NCBI
|
|
17
|
Shammas A, Degirmenci B, Mountz JM, McCook
BM, Branstetter B, Bencherif B, Joyce JM, Carty SE, Kuffner HA and
Avril N: 18F-FDG PET/CT in patients with suspected recurrent or
metastatic well-differentiated thyroid cancer. J Nucl Med.
48:221–226. 2007.PubMed/NCBI
|
|
18
|
Zhao H and Li H: Meta-analysis of
ultrasound for cervical lymph nodes in papillary thyroid cancer:
Diagnosis of central and lateral compartment nodal metastases. Eur
J Radiol. 112:14–21. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Renkonen S, Lindén R, Bäck L, Silén R,
Mäenpää H, Tapiovaara L and Aro K: Accuracy of preoperative MRI to
assess lateral neck metastases in papillary thyroid carcinoma. Eur
Arch Otorhinolaryngol. 274:3977–3983. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hempel JM, Kloeckner R, Krick S, Pinto Dos
Santos D, Schadmand-Fischer S, Boeßert P, Bisdas S, Weber MM,
Fottner C, Musholt TJ, et al: Impact of combined FDG-PET/CT and MRI
on the detection of local recurrence and nodal metastases in
thyroid cancer. Cancer Imaging. 16:372016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lou K, Gu Y, Hu Y, Wang S and Shi H:
Technetium-99m-pertechnetate whole-body SPET/CT scan in
thyroidectomized differentiated thyroid cancer patients is a useful
imaging modality in detecting remnant thyroid tissue, nodal and
distant metastases before 131I therapy. A study of 416
patients. Hell J Nucl Med. 21:121–124. 2018.PubMed/NCBI
|
|
22
|
Lee Y, Kim JH, Baek JH, Jung SL, Park SW,
Kim J, Yun TJ, Ha EJ, Lee KE, Kwon SY, et al: Value of CT added to
ultrasonography for the diagnosis of lymph node metastasis in
patients with thyroid cancer. Head Neck. 40:2137–2148. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garau LM, Rubello D, Morganti R, Boni G,
Volterrani D, Colletti PM and Manca G: Sentinel lymph node biopsy
in small papillary thyroid cancer: A meta-analysis. Clin Nucl Med.
44:107–118. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mulla M and Schulte KM: The accuracy of
ultrasonography in the preoperative diagnosis of cervical lymph
node (LN) metastasis in patients with papillary thyroid carcinoma:
A meta-analysis. Eur J Radiol. 81:1965.author reply 1966. 2012.
|
|
25
|
Na DK, Choi YJ, Choi SH, Kook SH and Park
HJ: Evaluation of cervical lymph node metastasis in thyroid cancer
patients using real-time CT-navigated ultrasonography: Preliminary
study. Ultrasonography. 34:39–44. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He Y, Pan MZ, Huang JM, Xie P, Zhang F and
Wei LG: Iodine-131: An effective method for treating lymph node
metastases of differentiated thyroid cancer. Med Sci Monit.
22:4924–4928. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hoang JK, Vanka J, Ludwig BJ and
Glastonbury CM: Evaluation of cervical lymph nodes in head and neck
cancer with CT and MRI: Tips, traps, and a systematic approach. AJR
Am J Roentgenol. 200:W17–W25. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mihailovic J, Prvulovic M, Ivkovic M,
Markoski B and Martinov D: MRI versus ¹3¹I whole-body
scintigraphy for the detection of lymph node recurrences in
differentiated thyroid carcinoma. AJR Am J Roentgenol.
195:1197–1203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Freudenberg LS, Antoch G, Frilling A,
Jentzen W, Rosenbaum SJ, Kühl H, Bockisch A and Görges R: Combined
metabolic and morphologic imaging in thyroid carcinoma patients
with elevated serum thyroglobulin and negative cervical
ultrasonography: Role of 124I-PET/CT and FDG-PET. Eur J Nucl Med
Mol Imaging. 35:950–957. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Morita S, Mizoguchi K, Suzuki M and Iizuka
K: The accuracy of (18)[F]-fluoro-2-deoxy-D-glucose-positron
emission tomography/computed tomography, ultrasonography and
enhanced computed tomography alone in the preoperative diagnosis of
cervical lymph node metastasis in patients with papillary thyroid
carcinoma. World J Surg. 34:2564–2569. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang W, Larson SM, Tuttle RM, Kalaigian H,
Kolbert K, Sonenberg M and Robbins RJ; Resistance of
[18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to
treatment with high-dose radioactive iodine, : Thyroid.
11:1169–1175. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Feine U, Lietzenmayer R, Hanke JP, Held J,
Wöhrle H and Müller-Schauenburg W: Fluorine-18-FDG and
iodine-131-iodide uptake in thyroid cancer. J Nucl Med.
37:1468–1472. 1996.PubMed/NCBI
|
|
33
|
Sun YG, Feng HJ, Liu JH, Hu R and Ouyang
W: Value of (18)F-FDG dual head coincidence imaging in predicting
the efficacy of radioiodine therapy for papillary thyroid carcinoma
with cervical lymph node metastasis. Nan Fang Yi Ke Da Xue Xue Bao.
31:1571–1574. 2011.(In Chinese). PubMed/NCBI
|
|
34
|
Weigel RJ and McDougall IR: The role of
radioactive iodine in the treatment of well-differentiated thyroid
cancer. Surg Oncol Clin N Am. 15:625–638. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang W, Macapinlac H, Larson SM, Yeh SD,
Akhurst T, Finn RD, Rosai J and Robbins RJ:
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography
localizes residual thyroid cancer in patients with negative
diagnostic (131)I whole body scans and elevated serum thyroglobulin
levels. J Clin Endocrinol Metab. 84:2291–2302. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mazzaferri EL and Jhiang SM: Long-term
impact of initial surgical and medical therapy on papillary and
follicular thyroid cancer. Am J Med. 97:418–428. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bardet S, Ciappuccini R, Quak E, Rame JP,
Blanchard D, de Raucourt D, Babin E, Michels JJ, Vaur D and Heutte
N: Prognostic value of microscopic lymph node involvement in
patients with papillary thyroid cancer. J Clin Endocrinol Metab.
100:132–140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ito Y, Miyauchi A, Jikuzono T, Higashiyama
T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Ichihara K and
Kuma K: Risk factors contributing to a poor prognosis of papillary
thyroid carcinoma: Validity of UICC/AJCC TNM classification and
stage grouping. World J Surg. 31:838–848. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
de Meer SG, Dauwan M, de Keizer B, Valk
GD, Borel Rinkes IH and Vriens MR: Not the number but the location
of lymph nodes matters for recurrence rate and disease-free
survival in patients with differentiated thyroid cancer. World J
Surg. 36:1262–1267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
de Castro TP, Waissmann W, Simões TC, de
Mello RC and Carvalho DP: Predictors for papillary thyroid cancer
persistence and recurrence: A retrospective analysis with a 10-year
follow-up cohort study. Clin Endocrinol (Oxf). 85:466–474. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wu Q, Zhang YM, Sun S, Li JJ, Wu J, Li X,
Zhu S, Wei W and Sun SR: Clinical and sonographic assessment of
cervical lymph node metastasis in papillary thyroid carcinoma. J
Huazhong Univ Sci Technolog Med Sci. 36:823–827. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Diab Y: Sentinel lymph nodes mapping in
cervical cancer a comprehensive review. Int J Gynecol Cancer.
27:154–158. 2017. View Article : Google Scholar : PubMed/NCBI
|
